Using advanced imaging techniques to improve gastric cancer staging

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the effectiveness of multi-parametric magnetic resonance imaging (mpMRI) and dual-energy computed tomography (DECT) in accurately staging gastric cancer before surgery. Gastric cancer is a leading cause of cancer-related deaths, and precise staging is crucial for determining the appropriate treatment. The study will include patients with confirmed gastric cancer who have not undergone prior therapy, utilizing advanced imaging techniques to enhance diagnostic accuracy. The findings could lead to improved individualized treatment plans based on more reliable staging results.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Consecutive patients with preoperative pathologically confirmed GC by endoscopy and preoperative imaging data (DECT/mpMRI) were included.
* No contraindications for CT/MRI examination
* Written informed consent

Exclusion Criteria:

* Patients with a history of previous therapy.
* Patients with recurrent gastric cancer
* Patients with a history of severe allergy to contrast agents
* Patients with imaging artefacts affect the evaluation

Where it's running

• Yu-Dong Zhang
  Nanjing, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI-assisted CT detection and staging of stomach cancer

  This project will test an AI tool that reads routine contrast-enhanced CT scans to detect stomach cancer and assign T1–T4 and N0–N3 stages before surgery.

  Recruiting The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07250347

• Risk prediction for gastric retention during sedated gastroscopy

  This study will test a simple grading system and prediction model to see if clinicians can identify which adults are likely to have significant stomach contents before sedated gastroscopy.

  Recruiting at 2 sites Zhejiang University · Hangzhou, Zhejiang and 2 other locations · NCT07104214

• Aspirin vs. rivaroxaban for blood clot prevention in newly diagnosed multiple myeloma

  In newly diagnosed multiple myeloma patients on IMiD-based therapy, this study tests whether aspirin or rivaroxaban is better at preventing blood clots.

  Recruiting Phase 4 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07907211

• Chemotherapy sensitivity-guided Culmerciclib combo for HR+/HER2- breast cancer before surgery

  This trial tests whether adding Culmerciclib to chemotherapy before surgery can help people with HR+/HER2- breast cancer who don’t respond to initial TAC treatment.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07900516

• Off-clamp, sutureless robot-assisted partial nephrectomy vs conventional robot-assisted partial nephrectomy

  This trial tests whether removing a small kidney tumor without clamping the blood supply and without stitching the kidney bed preserves kidney function better than the standard robot-assisted surgery.

  Recruiting The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07888608

• Chidamide, Lenalidomide, and Rituximab as induction therapy for newly diagnosed elderly or unfit double-expressor DLBCL

  This trial tests whether the combo of chidamide, lenalidomide, and rituximab can help treat newly diagnosed double-expressor DLBCL in people who are elderly or not fit for standard chemotherapy.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07884708

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.